Log in

NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

+0.04 (+0.75 %)
(As of 12/15/2019 08:25 AM ET)
Today's Range
Now: $5.36
50-Day Range
MA: $3.53
52-Week Range
Now: $5.36
Volume179,221 shs
Average Volume451,231 shs
Market Capitalization$93.26 million
P/E Ratio6.54
Dividend YieldN/A
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORMP



Sales & Book Value

Annual Sales$2.70 million
Cash Flow$0.83 per share
Book Value$1.12 per share


Net Income$-14,350,000.00
Net Margins-362.38%


Market Cap$93.26 million
Next Earnings Date1/13/2020 (Estimated)

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, January 13th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 brokerages have issued 1 year price objectives for Oramed Pharmaceuticals' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 151.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

What is the consensus analysts' recommendation for Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

Media stories about ORMP stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Oramed Pharmaceuticals.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 193,600 shares, an increase of 329.3% from the November 14th total of 45,100 shares. Based on an average daily trading volume, of 178,000 shares, the short-interest ratio is presently 1.1 days. Approximately 1.5% of the company's stock are short sold. View Oramed Pharmaceuticals' Current Options Chain.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tower Research Capital LLC TRC (0.11%) and Millennium Management LLC (0.09%). Company insiders that own Oramed Pharmaceuticals stock include Aviad Friedman, Leonard Sank and Nadav Kidron. View Institutional Ownership Trends for Oramed Pharmaceuticals.

Which major investors are buying Oramed Pharmaceuticals stock?

ORMP stock was acquired by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC and Millennium Management LLC. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Aviad Friedman and Leonard Sank. View Insider Buying and Selling for Oramed Pharmaceuticals.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $5.36.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $93.26 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel